Zynex (NASDAQ:ZYXI – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.200- for the period, compared to the consensus earnings per share estimate of 0.510. The company issued revenue guidance of $200.0 million-, compared to the consensus revenue estimate of $227.0 million. Zynex also updated its FY24 guidance to $0.20 EPS.
Zynex Stock Down 12.4 %
NASDAQ ZYXI traded down $1.26 during trading on Friday, hitting $8.93. 1,034,596 shares of the company traded hands, compared to its average volume of 124,147. Zynex has a 12 month low of $6.88 and a 12 month high of $13.77. The business has a fifty day simple moving average of $9.55 and a 200 day simple moving average of $11.06. The company has a current ratio of 3.58, a quick ratio of 2.87 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $283.71 million, a P/E ratio of 38.83 and a beta of 0.53.
Zynex (NASDAQ:ZYXI – Get Free Report) last posted its earnings results on Thursday, July 25th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). Zynex had a net margin of 3.12% and a return on equity of 13.14%. The company had revenue of $49.88 million for the quarter, compared to the consensus estimate of $51.99 million. During the same quarter last year, the business earned $0.09 earnings per share. Zynex’s quarterly revenue was up 11.0% on a year-over-year basis. As a group, sell-side analysts predict that Zynex will post 0.51 EPS for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on ZYXI
About Zynex
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Featured Stories
- Five stocks we like better than Zynex
- There Are Different Types of Stock To Invest In
- Why Call Options Volume for These 2 Stocks Spiked Together
- Upcoming IPO Stock Lockup Period, Explained
- MarketBeat Week in Review – 7/22 – 7/26
- Why Invest in High-Yield Dividend Stocks?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.